Our Business
Business details
Noile-Immune Biotech Inc. runs a business to develop safe and effective drugs for solid tumors employing state-of-art cancer immunotherapy with CAR-T cells using PRIME technology. These cells are exclusively licensed from Yamaguchi University and the Yamaguchi Technology License Organization, Ltd.
PRIME technology is expected to be exceptionally effective against cancer through administered CAR-T cells as well as the activation of endogenous immune cells in patients. PRIME is also a platform technology that can be applied to a wide range of regenerative medicine treatments, including a variety of cellular medicines and gene therapies that draw on the immune response to cancer. By combining this PRIME technology with treatment technology targeting different antigens expressed in solid tumors, we are developing a number of treatments for these tumors that use genetically modified immune cells.
We have established a hybrid business model with two elements: “in-house drug discovery,” i.e., drug discovery led by our company, and a “co-pipeline” in which drug development is pursued by licensing PRIME technology to other companies.
History
| April 2015 | Founded in Chuo Ward, Tokyo, as a venture-backed company originating from the National Cancer Center (NCC) and Yamaguchi University |
| September 2015 | Concluded a joint research agreement with Yamaguchi University |
| October 2015 | Obtained an exclusive license to the next-generation CAR T cell technology from Yamaguchi University with the right to sublicense it to third parties |
| August 2017 | Agreed to form a partnership on joint research with Takeda Pharmaceutical Company Limited (hereinafter, Takeda)1 |
| December 2018 | Concluded an out-licensing agreement for NIB102 and NIB103 with Takeda |
| March 2019 | Head office relocated to Minato Ward, Tokyo |
| August 2019 | Concluded a joint research agreement with Adaptimmune Therapeutics plc2 |
| November 2019 | Concluded a licensing agreement with Autolus Therapeutics plc3 |
| July 2020 | Takeda initiated a Phase I study on NIB102 |
| December 2021 | Takeda initiated a Phase I study on NIB103 |
| January 2022 | Initiated a Phase I study on the drug candidate NIB101 from our pipeline |
| August 2022 | Concluded a licensing agreement with Chugai Pharmaceutical Co., LTD. (hereinafter, Chugai) |
| June 2023 | Listed on the Tokyo Stock Exchange Growth Market |
Notes:
1. Our company has entered into the agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda
2. Our company has entered into the agreement with Adaptimmune Limited, a wholly owned subsidiary of Adaptimmune Therapeutics plc
3. Our company has entered into the agreement with Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc